cyclophosphamide + doxorubicin + peptichemio

This is a combination chemotherapy regimen consisting of three agents: - Cyclophosphamide, an alkylating agent that cross-links DNA strands and inhibits DNA synthesis, leading to cell death. - Doxorubicin (also known as Adriamycin), an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, resulting in the prevention of DNA replication and transcription. - Peptichemio, a peptide complex of m-L-phenylalanine mustard with both alkylating and antimetabolic properties. It acts by causing DNA damage through alkylation. Cyclophosphamide plus doxorubicin is a well-established combination used in the treatment of various cancers such as breast cancer and lymphomas[1][2][3][4]. Peptichemio has been evaluated primarily for solid tumors and lymphomas; it is less commonly used but has demonstrated some efficacy when combined with other agents[6][8]. The triple combination may be considered investigational or experimental, as there are no widely published protocols specifically for this exact three-drug regimen. Each drug contributes cytotoxic effects via distinct but complementary mechanisms targeting rapidly dividing cancer cells.